Yukie Yoshii - Search Results

Year	Number of Results
2008	1
2009	2
2010	3
2011	4
2012	2
2013	1
2014	4
2015	4
2016	2
2017	2
2018	3
2019	2
2020	2
2021	4
2022	4
2023	3
2024	0

1

Acetate/acetyl-CoA metabolism associated with cancer fatty acid synthesis: overview and application.

Yoshii Y, Furukawa T, Saga T, Fujibayashi Y. Yoshii Y, et al. Cancer Lett. 2015 Jan 28;356(2 Pt A):211-6. doi: 10.1016/j.canlet.2014.02.019. Epub 2014 Feb 22. Cancer Lett. 2015. PMID: 24569091 Review.

2

Trace Metal Impurities Effects on the Formation of [⁶⁴Cu]Cu-diacetyl-bis(N⁴-methylthiosemicarbazone) ([⁶⁴Cu]Cu-ATSM).

Shinada M, Suzuki H, Hanyu M, Igarashi C, Matsumoto H, Takahashi M, Hihara F, Tachibana T, Sogawa C, Zhang MR, Higashi T, Sato H, Kurihara H, Yoshii Y, Doi Y. Shinada M, et al. Among authors: yoshii y. Pharmaceuticals (Basel). 2023 Dec 21;17(1):10. doi: 10.3390/ph17010010. Pharmaceuticals (Basel). 2023. PMID: 38275997 Free PMC article.

3

Process to Remove the Size Variants Contained in the Antibody-Chelator Complex PCTA-NCAB001 for Radiolabeling with Copper-64.

Yoshii Y, Matsumoto H, Igarashi C, Tachibana T, Hihara F, Shinada M, Waki A, Yoshida S, Naito K, Ito K, Higashi T, Kurihara H, Ueno M. Yoshii Y, et al. Pharmaceuticals (Basel). 2023 Sep 22;16(10):1341. doi: 10.3390/ph16101341. Pharmaceuticals (Basel). 2023. PMID: 37895812 Free PMC article.

4

Identification and quantitative structure-activity relationship assessment of trace chemical impurities contained in the therapeutic formulation of [⁶⁴Cu]Cu-ATSM.

Igarashi C, Matsumoto H, Takahashi M, Hihara F, Tachibana T, Zhang MR, Kurihara H, Higashi T, Yoshii Y. Igarashi C, et al. Among authors: yoshii y. Nucl Med Biol. 2022 May-Jun;108-109:10-15. doi: 10.1016/j.nucmedbio.2022.02.001. Epub 2022 Feb 8. Nucl Med Biol. 2022. PMID: 35168008

5

A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma.

Tateishi K, Miyake Y, Kawazu M, Sasaki N, Nakamura T, Sasame J, Yoshii Y, Ueno T, Miyake A, Watanabe J, Matsushita Y, Shiba N, Udaka N, Ohki K, Fink AL, Tummala SS, Natsumeda M, Ikegaya N, Nishi M, Ohtake M, Miyazaki R, Suenaga J, Murata H, Aoki I, Miller JJ, Fujii Y, Ryo A, Yamanaka S, Mano H, Cahill DP, Wakimoto H, Chi AS, Batchelor TT, Nagane M, Ichimura K, Yamamoto T. Tateishi K, et al. Among authors: yoshii y. Cancer Res. 2020 Dec 1;80(23):5330-5343. doi: 10.1158/0008-5472.CAN-20-2425. Epub 2020 Oct 16. Cancer Res. 2020. PMID: 33067267

6

Efficacy of vorinostat-sensitized intraperitoneal radioimmunotherapy with ⁶⁴Cu-labeled cetuximab against peritoneal dissemination of gastric cancer in a mouse model.

Tachibana T, Yoshii Y, Matsumoto H, Zhang MR, Nagatsu K, Hihara F, Igarashi C, Sugyo A, Tsuji AB, Higashi T. Tachibana T, et al. Among authors: yoshii y. J Cancer Res Ther. 2022 Jul-Sep;18(4):907-914. doi: 10.4103/jcrt.JCRT_124_20. J Cancer Res Ther. 2022. PMID: 36149139 Free article.

7

Immuno-OpenPET: a novel approach for early diagnosis and image-guided surgery for small resectable pancreatic cancer.

Yoshii Y, Tashima H, Iwao Y, Yoshida E, Wakizaka H, Akamatsu G, Yamaya T, Matsumoto H, Yoshimoto M, Igarashi C, Hihara F, Tachibana T, Zhang MR, Nagatsu K, Sugyo A, Tsuji AB, Higashi T. Yoshii Y, et al. Sci Rep. 2020 Mar 10;10(1):4143. doi: 10.1038/s41598-020-61056-5. Sci Rep. 2020. PMID: 32157106 Free PMC article.

8

In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for Personalized ⁶⁴Cu-Intraperitoneal Radioimmunotherapy against Peritoneal Dissemination of Pancreatic Cancer: A Feasibility Study.

Hihara F, Matsumoto H, Yoshimoto M, Masuko T, Endo Y, Igarashi C, Tachibana T, Shinada M, Zhang MR, Kurosawa G, Sugyo A, Tsuji AB, Higashi T, Kurihara H, Ueno M, Yoshii Y. Hihara F, et al. Among authors: yoshii y. Int J Mol Sci. 2022 May 22;23(10):5807. doi: 10.3390/ijms23105807. Int J Mol Sci. 2022. PMID: 35628616 Free PMC article.

9

Preclinical Safety Evaluation of Intraperitoneally Administered Cu-Conjugated Anti-EGFR Antibody NCAB001 for the Early Diagnosis of Pancreatic Cancer Using PET.

Matsumoto H, Igarashi C, Tachibana T, Hihara F, Shinada M, Waki A, Yoshida S, Naito K, Kurihara H, Ueno M, Ito K, Higashi T, Yoshii Y. Matsumoto H, et al. Among authors: yoshii y. Pharmaceutics. 2022 Sep 12;14(9):1928. doi: 10.3390/pharmaceutics14091928. Pharmaceutics. 2022. PMID: 36145676 Free PMC article.

10

A limited overlap between intratumoral distribution of 1-(5-fluoro-5-deoxy-α-D-arabinofuranosyl)-2-nitroimidazole and copper-diacetyl-bis[N(4)-methylthiosemicarbazone].

Furukawa T, Yuan Q, Jin ZH, Aung W, Yoshii Y, Hasegawa S, Endo H, Inoue M, Zhang MR, Fujibayashi Y, Saga T. Furukawa T, et al. Among authors: yoshii y. Oncol Rep. 2015 Sep;34(3):1379-87. doi: 10.3892/or.2015.4079. Epub 2015 Jun 25. Oncol Rep. 2015. PMID: 26134305

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

38 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Results by year